Dapagliflozin for kidney and heart health after transplant
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a diabetes drug called dapagliflozin (Farxiga) can help protect your kidney function and heart health after a kidney transplant. It's for people who have had a transplant for at least a year and have diabetes or post-transplant diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You received a kidney transplant at least 1 year ago and your kidney function is in a certain range (eGFR 30-90).
- You have type 2 diabetes or diabetes that started after your transplant.
- Your blood pressure is well-controlled (below 130/80).
- You are not taking certain other diabetes medications called SGLT2 inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether dapagliflozin can preserve the structure and function of a kidney transplant. You may be asked to take dapagliflozin on top of usual transplant medicines to see if it helps the new kidney work better over time.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This trial tests two diabetes medications, empagliflozin and linagliptin, to see which one works better for controlling blood sugar, protecting kidney function, and improving body composition in people who have had a kidney transplant and have diabetes.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This study tests if the drug dapagliflozin (a medicine that helps protect the heart and kidneys) can improve recovery in patients who needed a breathing machine or blood pressure support in the ICU. If you qualify, you would take the drug after leaving the ICU to see if it lowers the risk of heart or kidney problems.
Hear when a new Kidney Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.